ADARx Pharmaceuticals

ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.

ADARx's vision is to provide effective and safe therapeutics to patients who suffer from intractable diseases.

ADARx was founded in 2019 by Zhen Li. The company is headquartered in San Diego, California.


ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.


ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.


ADARx currently havs 9 active programs in development. The company's lead product candidate, ADX-324, which is entering IND-enabling toxicology studies. ADARx's platform allows reproducibility and consistency with multiple mechanisms and a wide range of indications.


ADARx is backed by SR One Capital Management, OrbiMed, Lilly Asia Ventures, Sirona Capital, Ascenta Capital, and others. The company closed a $46M Series B-1 round on Jan 20, 2023. This brings ADARx's total funding to $132M to date.



  • Year founded: 2019
  • Funding Info: $132M over 4 Rounds (Latest Funding Type: Series B-1)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: San Diego
  • State: California
  • Country: United States
Related businesses